Biomarker FOXF2 for gastric cancer
AssigneeThe Chinese University of Hong Kong
InventorsJun Yu, Joseph Jao Yiu Sung
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for diagnosing and determining prognosis of gastric cancer in a subject by detecting suppressed expression of the FOXF2 gene, which in some cases is due to elevated methylation level in the genomic sequence of this gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating gastric cancer by increasing FOXF2 gene expression or activity.
Claims6
A method for identifying a human subject with an increased risk for gastric cancer, comprising the steps of:
- (a) determining the number of methylated CpGs in SEQ ID NO:
- 9 by treating genomic DNA from a gastric sample taken from a human subject with a bisulfite and amplifying the bisulfite treated genomic DNA with a primer pair comprising a primer comprising SEQ ID NO:
- 7 or SEQ ID NO:
- 8;
- and
- (b) identifying the human subject as having an increased risk for gastric cancer when the number of methylated CpGs in SEQ ID NO:
- 9 is greater than the number of methylated CpGs in SEQ ID NO:
- 9 in a control non-cancerous gastric sample.
A method for identifying a human gastric cancer patient with an increased likelihood of mortality from gastric cancer, comprising the steps of:
- (a) detecting methylation of SEQ ID NO:
- 9 by treating genomic DNA from a gastric cancer sample taken from a human gastric cancer patient with bisulfite and amplifying the bisulfite treated genomic DNA with a primer pair comprising a primer comprising SEQ ID NO:
- 7 or SEQ ID NO:
- 8;
- and
- (b) identifying the human gastric cancer patient as having an increased likelihood of mortality from gastric cancer when SEQ ID NO:
- 9 is methylated in the gastric cancer sample in comparison to a human gastric cancer patient that does not have methylation of SEQ ID NO:
- 9.
Dependencies are inferred from the claim text.